TScan Therapeutics Statistics
Total Valuation
TCRX has a market cap or net worth of $76.63 million. The enterprise value is $13.25 million.
Important Dates
The next estimated earnings date is Tuesday, May 5, 2026, before market open.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
TCRX has 60.10 million shares outstanding. The number of shares has increased by 15.88% in one year.
| Current Share Class | 55.82M |
| Shares Outstanding | 60.10M |
| Shares Change (YoY) | +15.88% |
| Shares Change (QoQ) | +128.84% |
| Owned by Insiders (%) | 0.21% |
| Owned by Institutions (%) | 43.23% |
| Float | 50.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.93 |
| Forward PS | 8.90 |
| PB Ratio | 0.55 |
| P/TBV Ratio | 0.58 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.28 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.41, with a Debt / Equity ratio of 0.76.
| Current Ratio | 8.41 |
| Quick Ratio | 8.15 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -48.33 |
Financial Efficiency
Return on equity (ROE) is -71.28% and return on invested capital (ROIC) is -30.10%.
| Return on Equity (ROE) | -71.28% |
| Return on Assets (ROA) | -27.88% |
| Return on Invested Capital (ROIC) | -30.10% |
| Return on Capital Employed (ROCE) | -63.69% |
| Weighted Average Cost of Capital (WACC) | 5.56% |
| Revenue Per Employee | $72,711 |
| Profits Per Employee | -$913,845 |
| Employee Count | 142 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -15.28% in the last 52 weeks. The beta is 1.01, so TCRX's price volatility has been similar to the market average.
| Beta (5Y) | 1.01 |
| 52-Week Price Change | -15.28% |
| 50-Day Moving Average | 1.05 |
| 200-Day Moving Average | 1.41 |
| Relative Strength Index (RSI) | 68.69 |
| Average Volume (20 Days) | 1,045,202 |
Short Selling Information
The latest short interest is 1.89 million, so 3.14% of the outstanding shares have been sold short.
| Short Interest | 1.89M |
| Short Previous Month | 1.89M |
| Short % of Shares Out | 3.14% |
| Short % of Float | 3.74% |
| Short Ratio (days to cover) | 3.16 |
Income Statement
In the last 12 months, TCRX had revenue of $10.33 million and -$129.77 million in losses. Loss per share was -$1.00.
| Revenue | 10.33M |
| Gross Profit | -102.23M |
| Operating Income | -133.81M |
| Pretax Income | -129.77M |
| Net Income | -129.77M |
| EBITDA | -130.95M |
| EBIT | -133.81M |
| Loss Per Share | -$1.00 |
Full Income StatementBalance Sheet
The company has $152.41 million in cash and $94.14 million in debt, with a net cash position of $58.27 million or $0.97 per share.
| Cash & Cash Equivalents | 152.41M |
| Total Debt | 94.14M |
| Net Cash | 58.27M |
| Net Cash Per Share | $0.97 |
| Equity (Book Value) | 123.12M |
| Book Value Per Share | 2.16 |
| Working Capital | 138.51M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$135.32 million and capital expenditures -$4.41 million, giving a free cash flow of -$139.73 million.
| Operating Cash Flow | -135.32M |
| Capital Expenditures | -4.41M |
| Depreciation & Amortization | 2.87M |
| Net Borrowing | n/a |
| Free Cash Flow | -139.73M |
| FCF Per Share | -$2.32 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | -1,296.01% |
| Pretax Margin | -1,256.81% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TCRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -15.88% |
| Shareholder Yield | -15.88% |
| Earnings Yield | -181.44% |
| FCF Yield | -195.36% |
Analyst Forecast
The average price target for TCRX is $7.00, which is 449.02% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.00 |
| Price Target Difference | 449.02% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (5Y) | 55.45% |
| EPS Growth Forecast (5Y) | -27.98% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
TCRX has an Altman Z-Score of -3.7 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -3.7 |
| Piotroski F-Score | 3 |
